ATAD2B

Across TCGA pan-cancer cohorts, ATAD2B RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ATAD2B’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where ATAD2B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ATAD2B is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

BLCA, HNSC, and KICH are the cancer types where ATAD2B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATAD2B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+0.717	<.001	10	view →
HNSC	All	All	+0.499	<.001	10	view →
KICH	Female	All	−0.803	<.001	7	view →
LUSC	Male	II,III,IV	+0.699	<.001	7	view →
STAD	All	II,III,IV	+0.612	.002	6	view →
BRCA	All	II,III,IV	+0.466	<.001	6	view →
LIHC	Female	All	+0.425	<.001	6	view →
THCA	All	All	−0.322	.001	6	view →
CHOL	Male	All	+1.333	<.001	5	view →
LUAD	All	All	+0.462	<.001	5	view →
UCEC	All	II,III,IV	+0.632	.006	4	view →
KIRC	All	All	+0.230	.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ATAD2B–BLCA

Open the BLCA breakdown →